Secondary myelodysplastic syndromes (MDS) are increasingly being reported after autologous transplantation. Transient dysplastic changes have also been observed after this type of treatment. However, to the best of our knowledge no systematic morphological analysis has been perfomed to determine the influence of stem cell transplantation on bone marrow morphology. In 53 patients undergoing autologous transplantation, we evaluated the bone marrow, before and 6 and 12 months after the transplant, in order to analyze the appearance of dyshemopoietic changes, assessed according to a pre-established score. We also studied 25 bone marrow samples obtained at the time of diagnosis, prior to treatment, but we did not find morphological atypia. Six months after transplant, cellularity and thrombopoiesis had decreased in 38% and 49% of patients respectively, although 1 year after the process they were normal in most cases. Myelodysplasia was already present in bone marrow before transplantation and continued to be in evidence for a long time afterwards. This suggests that chemotherapy and radiotherapy used prior to transplantation are responsible for dysplastic changes. The myeloid line was the most affected with 100% of patients showing dysgranulopoiesis 1 year after autografting. Cytopenias were observed in 51% and 44% of patients 6 and 12 months after transplantation. Moreover, concomitant presence of cytopenia and myelodysplasia was observed in 37.7% of patients at 6 months after transplantation and 25% at 12 months, and therefore they could be diagnosed with MDS. These data contrast with the incidence of secondary MDS reported in earlier publications. According to these findings, the value of the FrenchAmerican-British Co-operative Group criteria for the diagnosis of MDS following autologous transplantation is questionable. Moreover, since dyshemopoietic features are almost always present after autologous transplant, morphological criteria are not useful for early 
recognition of patients with secondary MDS after transplantation. Keywords: autologous transplantation; myelodysplastic features; FAB criteria; myelodysplastic syndromes Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are increasingly recognized as a late complication of stem cell transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Diagnosis of de novo MDS is usually based on the criteria of the French-American-British (FAB) Co-operative Group. 11 When patients present with peripheral cytopenias and dysplastic features alone in bone marrow and peripheral blood a diagnosis of refractory anaemia (RA) can be made (some of these cases may also have ring sideroblasts, RAS). Those patients who also display 10-30% of blasts would be diagnosed as RA with excess of blasts +/Ϫ in transformation. In addition, when Ͼ1000 monocytes/l are present, a diagnosis of chronic myelomonocytic leukemia is established. However, some authors have pointed out the difficulty in classifying MDS secondary to chemotherapy according to these criteria. [12] [13] [14] [15] Moreover, after transplantation, dysplastic features and cytopenias are frequently observed and these features could also interfere with a diagnosis of secondary MDS. However, the relationship between these dysplastic changes following stem cell transplantation and the transplant process itself is not well established since systematic analyses comparing bone marrow morphology before and after transplantation have not been performed.
The aim of the present study was to analyze the effect of autologous transplantation in the development of dyshemopoietic features and to determine the value of conventional criteria (cytopenias and dysplastic features) in the diagnosis of secondary MDS after transplantation. For this purpose, we evaluated the bone marrow before and 6 and 12 months after the transplant in 53 patients undergoing autologous transplantation, in order to analyze the appearance of dyshemopoietic changes, assessed according to a pre-established score. We observed that although a high proportion of cases (38%) show the coexistence of dysplastic changes in bone marrow together with cytopenias after transplantation, most of these cases already had these alterations before transplant. Accordingly, the influence of highdose chemotherapy in the development of MDS appears to be minimal. Moreover, the criteria for diagnosis of secondary MDS following transplantation should be reviewed.
Patients and methods

Patients
Fifty-three patients undergoing autologous stem cell transplantation for a hematological or non-hematological malignancy (10 acute leukemias, 24 lymphomas, 13 multiple myelomas, one chronic myeloid leukemia and five solid tumors) were included in the study. The median age was 43 years, with 27 males and 26 females. The source of stem cells was bone marrow (BM) in nine cases, peripheral blood (PB) in 38 cases and both, BM and PB, in the remaining six cases. None of the patients included in the study received any further treatment after transplantation and all were disease-free at the time of analysis, in order to avoid the influence of subsequent chemotherapy, radiotherapy or cytokines, or underlying disease on myelodysplastic changes. Prior to transplantation, patients received standard chemotherapy schemes (daunorubicin + ara-C for acute myeloid leukemia; CHOP, VECOP for non-Hodgkin's lymphoma; MOPP, ABVD, for Hodgkin's disease; CAF, super-CAF for breast cancer; VCMP/VBAD for multiple myeloma). For evaluation of the influence of alkylating agents, a series of dose modules was considered: 600 mg/m 2 of cyclophosphamide, 36 mg/m 2 of melphalan, 12 mg/m 2 of mechloretamine and 1400 mg/m 2 of procarbazine. Total alkylating effect was estimated from the sum of these modules. The median modules of alkylating agents received was 7.9. Four patients received radiotherapy prior to transplantation. In addition, in another three patients TBI was used as a conditioning regimen. The median doses of mononuclear cells, CD34
+ cells and CFU-GM were 6 × 10 8 /kg, 1.9 × 10 4 /kg and 17.9 × 10 6 /kg, respectively. Median times to recover more than 0.5 × 10 9 /l and more than 20 × 10 9 /l platelets were 13 and 21 days, respectively.
Morphological studies
Morphological evaluation of the BM was performed on samples obtained from the 53 patients both pre-transplantation and 6 months post-transplant. In 16 of these cases, the BM was also evaluated 1 year after the procedure. As a control group, we used samples from a separate group of 25 lymphoma patients (studied at diagnosis), before treatment and they were analyzed to determine whether there were dyshemopoietic changes before chemotherapy. Bone marrow aspirate smears were air-dried and stained with a May-Grünwald-Giemsa stain. The following cytological parameters were evaluated: bone marrow cellularity, proportion of blast cells, proportion of erythroblasts and bone marrow thrombopoiesis (the number of megakaryocytes was considered to have decreased when less than 10 megakaryocytes were observed in two slides). The following morphological features were used for the evaluation of dyshemopoiesis: (1) dyserythropoiesis: multinuclearity, nuclear fragments, abnormal nuclear shape, nuclear and cytoplasmic bridging, dysynchronous nuclear to cytoplasmic maturation, abnormal cytoplasmic features and megaloblastic changes; (2) dysgranulopoiesis: cytoplasmic hypogranulation, cytoplasmic hypergranulation, abnormal distribution of cytoplasmic granules, abnormal nuclear shape, megaloblastic changes and Pseudo-Pelger-Huët nuclear anomaly; (3) dysthrombopoiesis: micromegakaryocytes, large mononuclear forms and multiple small nuclei.
Dysplastic features were quantified using the score system devised by the Spanish Cooperative Group for the Study of Myelodysplastic Syndromes 16, 17 as shown in Table  1 . It assigns values depending on the grade of dyserythro-, dysgranulo-and dysthrombopoiesis. The final score had a potential range between 0 and 9 points.
Application of the FAB classification
The FAB criteria used for the diagnosis of MDS included both the presence of cytopenia in the absence of identified cause (not due to hemolytic anemia, bleeding or concomitant treatment) and bone marrow dysplastic features. For definition of cytopenia, we have considered the following values: Hb Ͻ100 g/l, leukocyte count Ͻ4 × 10 9 /l and platelet count Ͻ100 × 10 9 /l, and for myelodysplasia, the presence of at least marked dysplasia in one cell lineage, or mild in two cell lineages, on the bone marrow aspirate.
Statistical analysis
Paired comparisons were performed using the t-test and the Wilcoxon signed rank test. Comparison of categorical variables was made using 2 test. Dichotomical variables were compared through the Mann-Whitney U test. Two sides P values of 0.05 were taken as statiscally significant. 
Results
Morphological features
At the time of diagnosis, none of the patients had a hypocellular bone marrow. Before transplant, the bone marrow was hypercellular in 38% of patients and hypocellular in 21%. Six months after transplantation, the proportion of patients with hypocellularity increased to 38%, while 19% had a hypercellular bone marrow, but 1 year after the procedure cellularity became normal in 88% of cases ( Table 2 ). The number of megakaryocytes was decreased in 21% of patients before autologous transplantation and this percentage rose to 49% 6 months after transplantation and returned to 25% 1 year after the procedure (Table 3) . Bone marrow dysthrombopoiesis was significantly more frequent following transplantation (P = 0.008) (Table 3) , although this abnormality tapered with time. Polyploid megakaryocytes were the most common abnormality found, particularly 6 months post-transplantation (P = 0.01). Micromegakaryocytes were found in only one sample.
Regarding erythropoiesis evaluation, neither the percentage of erythroblasts nor the number of patients with dyserythropoiesis changed after transplant (Table 4 ). In acute leukemia patients, dyserythropoiesis was slightly higher although not significantly so.
Dysgranulopoiesis was severe in most patients both before (70%) and after (70-75%) transplantation (Table 5) . The most common feature of dysgranulopoiesis was the reduction and abnormal distribution of cytoplasmic granulation. More than 50% of myeloid cells were hypogranular in the three time points of the study. Six months after transplantation the number of patients with hypergranular granulocytes was significantly higher than before the procedure (P = 0.027).
In 40 of 53 patients analyzed 6 months after transplantation no blast cells were detected. In the remaining 13 cases the percentage of blasts ranged between 1% and 4%. 
FAB criteria
In our series 6 and 12 months after transplantation, cytopenias were observed in 50.9% and 43.7% of cases, respectively, while according to the defined criteria in Materials and methods, dysplastic features were present in 73.6% and 75%. Upon combining both features it was found that 37.7% and 25% of patients at 6 and 12 months after transplantation concomitantly showed the two criteria used by the FAB classification for diagnosis of RA.
Dysplasia score
When the score devised by the Spanish Cooperative Group for the Study of the MDS was applied to this series of patients it showed that at diagnosis, the score was very low (0.6 Ϯ 0.7), indicating that lymphoma patients do not show dysplastic features at diagnosis. By contrast, before and after transplant, the score for myelodysplasia significantly increased (P = 0.000). Prior to transplantation dyshemopoiesis was already present and it persisted 1 year after the procedure without differences between the results obtained pre and post-transplantation (Table 6 ). There was no difference in the score of myelodysplasia according to the presence of cytopenias in peripheral blood and source of progenitors used for transplantation (bone marrow, peripheral blood) (Table 7) . Moreover, no significant differences in myelodysplastic features were found between acute leukemia cases and the other patient group after transplantation. In addition, neither the dose of alkylating agents nor the use of radiotherapy prior to autograft influenced the myelodysplastic score.
Discussion
Secondary MDS is a late complication of anti-neoplastic therapy and over the last few years it has been increasingly Results are expressed as percentage of granulocytes. MeanϮ standard deviation and median (range). Comparison between hypergranular granulocytes pre-transplantation vs 6 months after transplantation: P = 0.027.
Table 6
Myelodysplasia score
Results are given as mean Ϯ standard deviation and median (range).
a
Comparison between the score at diagnosis and at the other time points of the study (P = 0.000).
b
Comparison between the score pre-transplantation vs 6 months and vs 12 months after transplantation (P Ͼ 0.05).
reported after autologous stem cell transplantation with an incidence ranging from 1-18% at 5-6 years. 1-10 Diagnosis of MDS is usually based on the FAB Cooperative Group criteria 11 of peripheral blood cytopenias and dyshemopoietic features in the bone marrow and peripheral blood. Previous studies have shown that dyshemopoiesis is a frequent bone marrow finding after autologous transplantation, 12,18-21 but a systematic study of these morphological changes has never been performed. Here, we studied the morphological characteristics of the bone marrow from a series of patients undergoing hematopoietic stem cell transplantation in order to find out whether the transplantation procedure could account for these dysplastic changes.
Information about the influence of transplantation on bone marrow cellularity is scanty. [21] [22] [23] [24] We have observed that the transplant process induces hematopoietic damage, increasing the number of cases with decreased cellularity and thrombopoiesis 6 months after the procedure. However, this damage is transitory since these parameters return to normal in most patients 1 year after transplantation.
Regarding dyshemopoiesis, we have found that bone marrow already showed dysplastic features before transplantation and that these abnormalities were still present 12 months after the procedure. It should be noted that in contrast, we did not find morphological atypia in samples obtained at diagnosis. This suggests that dysplastic changes are not a transitory event following autologous transplantation and that chemo/radiotherapy treatments used prior to transplantation are responsible for the dyshemopoiesis.
There have only been a limited number of studies concerning morphological changes following transplan- Table 7 Myelodysplasia score depending on the presence of peripheral cytopenias and source of progenitor cells
Cytopenias
Source of progenitor cells
12 months after transplantation 3 Ϯ 0.6 2.7 Ϯ 0.7 3 2.9 Ϯ 0.7
Results are given as mean Ϯ standard deviation and median (range). BM = bone marrow; PB = peripheral blood.
tation. [18] [19] [20] The most commonly observed abnormality in our analysis was the alteration in myeloid granularity, which is concordant with other reports. 15, 18, 20 In an ultrastructural study, Masat et al 20 observed that the number of azurophilic granules decreases after transplantation and the number of secondary or tertiary granules increases. In accordance with these data, we detected hypergranularity in the myeloid lineage more frequently 6 months after transplantation than before. Investigation of dyserythropoietic and dysthrombopoietic atypias has been previously restricted to the early post-transplant period (first 12 weeks) after transplantation. [19] [20] [21] Transient dyserythropoiesis has been reported to be present in all cases 60 days following transplantation. 20 We have found that dyserythropoietic changes persist in some cases for a long time after autografting, although usually only a minority of erythroblasts are affected. It has been reported that thrombopoiesis is the most damaged cell lineage post-transplant and this parameter is a good indicator of the graft function. 22, 23 In our experience, in the megakaryocyte line, the most relevant feature is the decreased number of megakaryocytes found in almost half of patients at 6 months after transplantation together with the existence of a significant increase in dysthrombopoietic features at this post-transplant point. Nevertheless, these abormalities recover 1 year after transplantation.
Since 1982, the FAB Cooperative Group criteria have been very useful for the diagnosis of de novo MDS. In recent years some criticisms have arisen because these criteria do not specify the degree of cytopenias and myelodysplasia necessary to consider a patient as having MDS-type refractory anemia. 13, 14, 25 Moreover, according to our data a high percentage of transplanted cases could be diagnosed as secondary according to the FAB criteria 12, 14 (38% of cases at 6 months post-transplant and 25% at 12 months, could be classified as RA). These data contrast with the reported incidence for secondary MDS after autotransplantation (1-18%). Peripheral blood values can normalize progressively after transplant although in some cases this occurs even years after the procedure, MDS is an incurable disease and for that reason we must be very cautious about diagnosing it after transplantation, if diagnosis is based on morphological criteria alone. Other parameters such as cytogenetic or clonality analysis must be considered. Both methods have been proven to detect hematopoietic abnormalities in MDS before morphological or clinical evidence of disease. [26] [27] [28] Nevertheless, it has recently been demonstrated, using in situ hybridization, that cytogenetic aberations associated with post-transplant MDS were present in hematopoietic cells prior to transplantation. 29, 30 This suggests that hematopoietic damage may result from prior chemotherapy, and a diagnosis of post-transplantation MDS can only be established if appropiate pre-transplantation investigations have been carried out. Moreover, a systematic study of cytogenetic abnormalities should be mandatory in all patients before they undergo stem cell transplantation.
